Skip to content
The Journal

What we read.
What changed.

Explainers (free). News on real changes (paid). Corrections when we’re wrong (free). What we read this week (paid). Updates as we make them, dated, sourced.

  1. Explainer7 min · Free

    How to evaluate any RUO peptide vendor.

    We won't name vendors. We will tell you exactly what to check before you spend money on one. The 11-point checklist most peptide-Discord regulars run mentally before every order.

    sourcingfield-guideruovendor-evaluation
  2. Explainer5 min · Free

    What an honest COA actually looks like.

    A real Certificate of Analysis is a one-page document with five things on it. The fake ones are missing at least one. Here's how to tell at a glance.

    sourcingfield-guidecoavendor-evaluation
  3. Explainer6 min · Free

    7 red flags in any peptide Telegram or Discord group.

    Peptide chats are where group buys happen. They're also where scams happen. Pattern-recognition for the gray-market layer most beginners walk into blind.

    sourcingfield-guidegray-marketvendor-evaluation
  4. Explainer6 min · Free

    How to run an ID test before you trust a vendor.

    $80 of mass spec testing is the cheapest insurance in the protocol. Here's exactly how to send a sample, who to send it to, and how to read the result.

    sourcingfield-guidevendor-evaluationtesting
  5. Explainer5 min · Free

    How to read a vendor's mass spec report.

    A walkthrough of what each section of a mass spectrometry report means, where the lies hide, and how to validate the result against the published molecular weight.

    sourcingfield-guidecoatesting
  6. Explainer8 min · Free

    How peptides actually get to your door.

    The four-tier supply chain nobody publishes plainly. Brand pharmacy → 503A compounder → US RUO reseller → Discord/Telegram gray market. Same molecule, four prices, four risk profiles.

    sourcingfundamentalsgray-market
  7. Explainer4 min · Free

    What the hell is a peptide.

    Short answer: a small chain of amino acids your body uses as a signal. Long answer below.

    fundamentalsnewbie
  8. What we read5 min · Paid

    We read 14 new studies this week. Three change something.

    Tirzepatide vs Sema head-to-head update, retatrutide phase 3 readout interim, and a real signal on SS-31 in dry AMD.

    weeklytirzepatideretatrutidess-31
  9. News2 min · Paid

    Lilly files orforglipron with the FDA.

    The first oral GLP-1 with phase 3 evidence is now in front of the FDA. Decision likely H2 2026 or 2027.

    glp-1orforglipronfda
  10. News2 min · Paid

    SS-31 (elamipretide) gets first FDA approval — Barth syndrome.

    Stealth BioTherapeutics' Forzinity approved at 40mg/d. The first cardiolipin-targeting peptide to clear the FDA. Dry AMD is the bigger prize.

    ss-31fdarare-disease
  11. Correction1 min · Free

    We were wrong about CJC-1295 dosing.

    Original page said 100mcg 3×/wk. The published Teichman 2006 PK paper used a single 60mcg/kg dose. Math fixed.

    cjc-1295dosing
  12. News3 min · Free

    MK-677 phase 2b CHF signal confirmed in re-analysis.

    Pooled analysis of two terminated trials shows 6.5% vs 1.7% heart-failure incidence at 25mg/d. We've added a stronger flag to the MK-677 page.

    mk-677safetyghs
  13. News3 min · Free

    Semaglutide compounding fully restricted — final FDA enforcement.

    503A pharmacies got 60-day notice. Compounded sema effectively dead in the US for personal-use scripts. Tirzepatide compounding still in safe-harbor.

    semaglutidecompoundedfdaindustry
  14. News3 min · Paid

    TRIUMPH-3 retatrutide 12mg confirmed at 88-week primary endpoint.

    24.4% mean weight loss at 88 weeks. The 12mg arm holds. Lilly will submit obesity NDA in Q3 2026.

    retatrutidephase-3glp-1
Want the deep dives the journal references?

The journal is free. The reports are $19.

Every post here links into a peptide deep-dive. $19 per peptide for the full report — mechanism, evidence, dose, sourcing, safety, editorial position — or $29/mo for all of them plus the OS.

See plans →